The Staying Safe Intervention: Preventing HCV Among Young Opioid Injectors

This study assesses the effectiveness of the Staying Safe (Ssafe) intervention in reducing both injection-related Hepatitis C (HCV) and HIV risk behavior, and HCV incidence among young adults (ages 18-29) who inject opioids (heroin and/or prescription opioids). Ssafe is an innovative, strengths-based, socio-behavioral HCV prevention intervention found in preliminary research to be highly acceptable and feasible, with strong indications of efficacy. The proposed trial promises to significantly advance our ability to prevent HCV infection in the growing population of young, prescription opioid-initiated injectors.

Project Investigators
Project Staff
Related Publications